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Bilirubin (a heme oxygenase-1 metabolite), the end product of heme catabolism, is a potent endogenous antioxidant.1,2 
Numerous studies have shown an inverse association between 
bilirubin levels and several oxidative stress–mediated diseases 
such as coronary artery disease, diabetes mellitus, metabolic 
syndrome, cardiovascular disease, and colorectal cancer.3–6 
According to the first report on the association between bilirubin 
level and stroke in 2003,7 plasma bilirubin concentration might 
serve as a useful marker of oxidative stress in patients with hem-
orrhagic stroke. Since then, similar results have been reported 
in both Western8,9 and Asian10,11 countries. However, Arsalan et 
al12 have reported that higher serum bilirubin levels are associ-
ated with increased stroke severity, longer hospitalization, and 
poor prognosis. Therefore, the role of bilirubin as a risk factor 
or prognostic factor for stroke is uncertain because of poten-
tial confounding factors. Given the limitations of observational 
studies, whether the association between bilirubin and stroke is 
causal or because of residual confounding remains unknown.
Mendelian randomization uses genetic variants randomly 
allocated according to Mendel’s second law without any pre-
conception.13,14 As instrumental variables (IV) for Mendelian 
randomization analysis, studies on genetic polymorphisms in 
major bilirubin related genes such as uridine diphosphogluc-
uronyltransferase (UGT1A1), solute carrier organic anion 
transporter family member 1B1, and solute carrier organic anion 
transporter family member 1B3 have been reported.15–17 In par-
ticular, rs6742078 in UGT1A1, a single-nucleotide polymor-
phism (SNP) that explains 18% of the variation in total serum 
bilirubin levels is well known as a critical region related to bili-
rubin.15 In addition, data from numerous studies have suggested 
that stroke is markedly heritable. The proportion of variance 
explained by a shared genetic background ranges from 0.37 to 
40.3.18 However, to the best of our knowledge, Mendelian ran-
domization on bilirubin with stroke has not been reported yet.
With the assumption that bilirubin is a strong mediator 
between genes and stroke, the causal effects of bilirubin on 
stroke can be determined using a genetic marker through 
Mendelian randomization analysis. Using the KCPS-II 
(Korean Cancer Prevention Study-II) Biobank Cohort, we 
hypothesized that lower levels of serum bilirubin would 
increase stroke because of bilirubin gene variations.
Methods
Participants
The KCPS-II Biobank was initiated in April 2004. It was supported 
by the Seoul City Government in December 2005 as a project of the 
Korean Metabolic Syndrome Research Initiative study. Blood sample 
collection from participants in the KCPS-II Biobank was initiated in 
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2004 at 2 hospitals (Severance Hospital, Bundang Cha Hospital) on 
a small scale. It has been expanded to 11 hospitals since April 2006. 
These 11 health promotion centers located in Seoul and Gyeonggi 
province consist of a population of 18 879 351 (≈40.9% of the total 
South Korea’s population of 46 136 101) based on a 2000 report.19 
Study members were participants in routine health assessments at 
health promotion centers across Seoul and Kyong-gi province, South 
Korea. Specifically, the number of participants who had provided 
informed content in the 11 health promotion centers between 2004 
and 2013 was 159 844. Five thousand participants were randomly 
selected as a subcohort of KCPS-II Biobank participants. A total of 
850 stroke cases were reported from main cohort. Final study partici-
pants were 5599 men and women in 2016 (Figure I in the online-only 
Data Supplement). The Severance Medical Ethics Committee of the 
Korean approved this study (no. 4-2011-0277). All participants gave 
written informed consent.
Data Collection
Baseline information was obtained from health examinations per-
formed from 2004 to 2013. Each participant completed systemized 
questionnaires including smoking habit (never smoker, ex-smoker, or 
current smoker), alcohol habit (nondrinker or drinker of any amount 
of alcohol), regular exercise (yes or no), and other characteristics such 
as medical history and any medications. Weight, height, and blood 
pressure were measured for participants in a standardized manner.
The body mass index was calculated as weight in kilograms 
divided by height in meters squared. Systolic and diastolic blood 
pressures were measured in a seated position with a mercury sphyg-
momanometer or automatic manometer. Fasting blood glucose, 
serum cholesterol, and serum bilirubin concentrations were measured 
through automated biochemical profiling (Hitachi-7600 analyzer; 
Hitachi Ltd). Bilirubin concentrations were collected in milligram 
per deciliter units.
Measurement of Outcome
Outcome variables were incidence of stroke and its subtypes (isch-
emic, hemorrhagic, and all stroke types) as recorded in hospital 
admission discharge records from 2005 to 2014 (median follow-up 
duration, 7.0 years). We ascertained these outcomes from health 
insurance claim data from the National Health Insurance Service.10 
We checked fatal cases from the national death certification data.10 
Ischemic, hemorrhagic, and all stroke types were defined according 
to the International Classification of Diseases-Tenth Revision codes: 
ischemic stroke, I63–I639; hemorrhagic stroke, I60–I629; and all 
stroke types, I60–I699. For those individuals with more than 1 stroke 
event during the follow-up period, only the first event was consid-
ered in our statistical analyses. The accuracy rate of the International 
Classification of Diseases codes for cerebrovascular diseases in med-
ical insurance claims for men in Korea was reported to be 83.0% in 
2000.20
DNA Extraction and SNP Analysis
Biological samples for DNA extraction used in the present study 
were obtained from KCPS-II Biobank at baseline. UGT1A1 geno-
typing was conducted for 5000 men and women in 2016. These par-
ticipants were randomly selected as a subcohort of KCPS-II Biobank 
participants. Genotype data were produced using the Korean Chip 
(K-CHIP) available through the K-CHIP consortium. K-CHIP was 
designed by Center for Genome Science, Korea National Institute 
of Health, Korea (4845-301, 3000–3031). The Korean chip contains 
830 000 SNPs with no imputation of SNPs.
Statistical Analysis
The association between bilirubin and SNP through GWAS was 
tested by an additive model of linear regression analysis after 
adjusting for age and sex using PLINK 1.07.21 We used Haploview 
(v4.1) to generate Manhattan plots of −log10 P, linkage disequilib-
rium structures, and haplotype block plots. Weighted genetic risk 
score (WGRS) was calculated using 14 SNPs after excluding the 
use of r2>0.9 in SNPs obtained from the genome-wide association 
study (GWAS) to investigate causal effect of bilirubin on stroke 
(Figures II and III in the online-only Data Supplement). The esti-
mate is analyzed by the linear regression between the association 
of the number of risk allele and bilirubin. And then, the WGRS was 
calculated by multiplying each estimated β-coefficient by the num-
ber of corresponding risk alleles (0, 1, or 2). Observational multi-
variable cox proportional hazard model was performed using for 
association between bilirubin and stroke, while adjusting for con-
founding variables.
Mendelian randomization analysis was performed in three steps. 
First, linear regression was used to assess the strength of the asso-
ciation of UGT1A1 variants (rs6742078) and WGRS with bilirubin 
levels and determine whether the association was fully mediated by 
bilirubin levels. The strength of the association was expressed as 
F statistics. We used linear regression under the assumption of an 
additive genetic model. Second, we examined the association of 
rs6742078 and WGRS with participants’ characteristics. Third, the 
association between stroke and bilirubin through GWAS was tested 
by cox proportional hazard model. A 2-sided significance level of 
α=0.05 was used. All statistical analysis was performed using SAS 
9.2 (SAS Institute Inc, Cary, NC) and STATA/IC 13.1 (Stata Corp LP, 
College Station, TX).
Results
Total Serum Bilirubin Levels 
Among Study Participants
The characteristics of the study participants are summarized in 
Table 1. Bilirubin levels were measured for 5599 participants 
(4793 subcohort and 806 incident stroke) from the KCPS-II 
Biobank. Mean±SD of bilirubin concentration was 0.91±0.35 
mg/dL (0.98±0.35 mg/dL in men [n=3745] and 0.77±0.30 mg/
dL in women [n=1854]). During a 7-year follow-up, a total 
of 806 men and women were hospitalized because of stroke 
(Table 1).
Table 1. Baseline Characteristics of Study Subjects and Their 
Associations With Incident Stroke Using Cox Proportional 
Hazard Model
 
Subcohort 
(n=4793)
Incident Stroke* 
(n=806) HR (95% CI)
Age, y 42.4 (8.9) 52.2 (11.4) 1.073 (1.065–1.081)
Total bilirubin, 
mg/dL
0.92 (0.35) 0.84 (0.35) 0.685 (0.530–0.887)
Systolic BP, mm Hg 118.2 (14.2) 125.0 (16.1) 1.012 (1.007–1.017)
Fasting glucose, 
mg/dL
90.7 (18.5) 98.0 (25.6) 1.003 (0.999–1.006)
Total cholesterol, 
mg/dL
190.3 (33.2) 197.0 (35.1) 1.003 (1.001–1.006)
HDL-cholesterol, 
mg/dL
50.8 (10.0) 49.9 (11.4) 0.992 (0.984–1.000)
Sex (female), % 33.2 32.6 1.028 (0.831–1.299)
Smoking status, %
  Ex-smoker 19.8 22.1 0.942 (0.736–1.206)
  Current smoker 31.6 30.2 1.237 (1.016–1.596)
Data are expressed as mean (SD) unless otherwise indicated. BP indicates 
blood pressure; CI, confidence interval; HR, hazard ratio; and HDL, high-density 
lipoprotein.
*Stroke incidence cases in subcohort included incident stroke group.
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Genome-Wide Association With 
Total Serum Bilirubin Levels
A genome-wide association with total serum bilirubin levels 
was tested in 5599 individuals from the KCPS-II biobank to 
identify genetic factors affecting serum bilirubin levels. As 
shown in Figure IV in the online-only Data Supplement, sig-
nificant associations were observed on chromosome 2 located 
in the promoter of UGT1A1 gene. Among the 3 most signifi-
cant UGT1A1 SNPs, rs887829 showed the strongest asso-
ciation with bilirubin levels (P=1.29E−82). The second most 
significant variant in this gene was rs6742078 (P=2.33E−82). 
Both variants had the same effect on bilirubin levels (0.207 
mg/dL per copy of the minor allele C and G, respectively; 
Table I in the online-only Data Supplement).
Association of rs6742078 and WGRS 
With Risk Factors of Stroke
To account for potential confounding bias, we tested whether 
rs6742078 and WGRS were associated with common stroke 
risk factors (Table 2). Genotype frequencies of rs6742078 
for genotypes GG, GT, and TT were 77.7%, 20.8%, and 
1.5%, respectively. Mean bilirubin level was the highest 
in rs6742078*TT carriers (1.4±0.5 mg/dL; n=82). It was 
lower in rs6742078*TG (1.1±0.4 mg/dL; n=1168) and 
rs6742078*GG (0.9±0.3 mg/dL; n=4349) carriers (P<0.0001; 
Table 2; Figure 1). As shown in Table 2, no significant differ-
ences across genotype groups and WGRS were found in age, 
sex, body mass index, systolic blood pressure, fasting serum 
glucose, total cholesterol level, high-density lipoprotein-
cholesterol level, hypertension, or diabetes mellitus. Notably, 
genotypes were significantly related to smoking status. A total 
of 70.7% of the rs6742078*TT carriers were never smokers, 
whereas a total of 47.9% of the rs6742078*GG carriers were 
never smokers. A total of 31.8% of the rs6742078*GG carri-
ers were current smokers, whereas 19.5% (P=0.0018) of the 
rs6742078*TT carriers were current smokers. Overall, both 
rs6742078 and WGRS were associated with bilirubin level but 
these were not related confounding variables.
Causal Estimates for the Effect 
of Bilirubin on Stroke
Using the highly associated SNP rs6742078, and WGRS of top 
14 SNPs, we performed Mendelian randomization to inves-
tigate whether bilirubin levels had a causal effect on stroke 
Table 2. Associations Between UGT1A1 Polymorphism rs6742078 or WGRS Using 14 Single-Nucleotide 
Polymorphisms From Bilirubin Genome-Wide Association Study and Total Bilirubin Level in KCPS-II (Korean 
Cancer Prevention Study-II) Biobank Participants
 UGT1A1 Polymorphism rs6742078 WGRS
 GG (n=4349) TG (n=1168) TT (n=82) P Value* r or Mean (SD) P Value*
Total bilirubin, mg/dL 0.9 (0.3) 1.1 (0.4) 1.4 (0.5) <0.0001 0.369 <0.0001
Age, y 43.7(9.9) 43.9(9.8) 45.0(10.9) 0.473 0.017 0.218
Body mass index, kg/m2 23.8 (3.0) 23.9 (3.1) 23.9 (3.4) 0.816 0.024 0.071
Systolic BP, mm Hg 119.2 (14.7) 119.4 (14.6) 118.3 (17.3) 0.738 0.007 0.611
FSG, mg/dL 91.8 (19.7) 91.7 (20.0) 90.0 (23.5) 0.689 0.019 0.166
Total cholesterol, mg/dL 191.3 (33.5) 191.3 (34.1) 189.9 (31.3) 0.935 -0.020 0.138
HDL-cholesterol, mg/dL 50.7 (10.3) 50.4 (9.8) 52.4 (10.9) 0.198 -0.012 0.365
Sex men 67.1 66.9 57.3 0.177 0.52 (0.30) 0.066
Women 32.9 33.1 42.7  0.50 (0.29)  
Smoking status, %
  Never 47.9 48.5 70.7 0.002 0.51 (0.30) 0.854
  Ex-smoker 20.3 20.4 9.8  0.51 (0.29)  
  Current 31.8 31.1 19.5  0.52 (0.29)  
Hypertension, %†
  No 81.8 81.6 86.6 0.523 0.51 (0.29) 0.782
  Yes 18.2 18.4 13.4  0.52 (0.30)  
Diabetes mellitus, %‡
  No 94.3 94.3 96.3 0.7247 14.3 (4.6) 0.934
  Yes 5.7 5.7 3.7  14.4 (4.8)  
BP indicates blood pressure; FSG, fasting serum glucose; HDL, high-density lipoprotein; UGT1A1, uridine diphosphoglucuronyltransferase; 
and WGRS, weighted genetic risk score.
*P value from ANOVA for continuous variables or from χ2 test for categorical variables.
†Systolic blood pressure ≥140 mm Hg or diastolic blood pressure ≥90 mm Hg or treatment history.
‡FSG ≥126 mg/dL or treatment history.
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(Table 3). After adjusting for age, sex, systolic blood pressure, 
fasting serum glucose, total cholesterol, high-density lipo-
protein-cholesterol, and smoking status, the F statistic for the 
association of WGRS with bilirubin level was higher than of 
rs6742078 (F
rs6742078=138; FWGRS=187), indicating that WGRS 
was a valid instrument for bilirubin levels. The bilirubin lev-
els significantly decreased the risk of stroke in observational 
multivariate hazard ratio (HR
rs6742078=0.67; 95% confidence 
interval, 0.51–0.87; HRWGRS=0.70; 95% confidence interval, 
0.53–0.91) even after adjusting for confounding variables 
(Figure 2). However, such association was not significant in 
IV analysis (P
rs6742078=0.531; PWGRS=0.240).
Discussion
Our study revealed no evidence of a causal role between 
serum bilirubin level and stroke risk although strong associa-
tions between serum bilirubin level and stroke risk have been 
reported in previous observational studies. We showed that 
serum bilirubin level was associated with stroke in an ordi-
nary least-squares analysis. However, using rs6742078 and 
the WGRS with 14 SNPs selected from our GWAS of serum 
bilirubin as instrument variables in the 2-stage least-squares 
Mendelian randomization analysis, we observed no causal 
relationship between serum bilirubin level and stroke risk. A 
previous Mendelian randomization study16 showed an inverse 
association of bilirubin with cardiovascular disease risk fac-
tors such as body mass index or cholesterol. This study is in 
line with our study results, confirming that bilirubin-associ-
ated genes are not causal.
Bilirubin and Stroke Risk in Observational Studies
We confirmed the previous findings that elevated bilirubin 
levels were associated with reduction in the risk of stroke.9–12 
Also, there was statistically significant evidence that serum 
total bilirubin level was independently associated with car-
dioembolic stroke, so that the level can be used as a measure 
to diagnose that stroke subtype.22 Moreover, another study 
proved that serum bilirubin levels were positivity associated 
with severity of acute ischemic stroke with higher adjusted 
odds ratio of severity in the top quartile of total bilirubin and 
direct bilirubin.23 The association between bilirubin levels and 
stroke risk gradually decreased after adjusting for age, sex, sys-
tolic blood pressure, fasting serum glucose, total cholesterol, 
high-density lipoprotein-cholesterol, and smoking status, sug-
gesting that the previous observational studies showing the 
association between bilirubin levels and stroke risk9,10 might 
have been confounded by these variables. Moreover, the asso-
ciation may disappear after adjusting for unknown possible 
confounding variables, resulting in no evidence of association 
between bilirubin levels and stroke. Therefore, the effect of 
bilirubin levels on stroke remains inconclusive in conven-
tional observational studies.
Genetic Polymorphisms and Bilirubin Levels
UDP-glucuronosyltransferases (UGTs) are a family of 
membrane-bound enzymes involved in the conjugation of 
endogenous such as bilirubin with UDP-glucuronic acid.24 In 
this study, we confirmed the large contribution of UGT1A1 
to human serum bilirubin levels. Three genetic variants 
(rs887829, rs6742078, and rs10929302) at the UGT1A1 
locus were found to be associated with bilirubin levels. The 
strongest association was found between variant rs887829 
(P=1.29E−82) and bilirubin level, which was strongly linked 
to the other 2 variants.
These results are consistent with previous GWAS. SNP 
rs887829 at UGT1A1 has the lowest P value in Europeans25 
and blacks.26 SNP rs6742078 is the most significant SNP 
located in UGT1A1 in Europeans27 and the third most signifi-
cant variants in Korean populations.28
Consistent with the previous GWAS performed in Korean 
populations,28 we found that 2 top SNPs (rs887829 and 
rs6742078) were strongly linked to each other. Interestingly, 
Johnson et al27 have reported that rs6742078 is in strong link-
age disequilibrium (r2=0.88) with functional promoter poly-
morphism UGT1A1*28, indicating that UGT1A1*28 might 
be polymorphism associated with serum bilirubin levels in the 
UGT1A1 locus. Thus, the major association of the UGT1A1 
promoter region might be derived from the functional pro-
moter polymorphism of UGT1A1*28 in which the longer 
TATAA element can result in a 5-fold reduction in promoter 
activity. Bosma has found that mutations in this gene are 
Figure 1. Associations between rs6742078 genotypes (GG, TG, 
and TT; A) or weighted genetic risk score (B) using 14 single-
nucleotide polymorphisms related to bilirubin in chromosome 2 
or 12 and total serum bilirubin levels.
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responsible for Crigler–Najjar syndrome and mild unconju-
gated hyperbilirubinemia of Gilbert syndrome.29
Genetic Polymorphisms and Stroke Risk
Ekblom et al30 have found that there is no evidence for a pro-
tective effect of the UGT1A1*28 polymorphism or bilirubin 
against stroke. These findings suggest that other factors influ-
encing the risk of stroke might also affect bilirubin levels.30 
However, the latter finding is inconsistent with the results of 
the current study or previous studies.15–17 The risk of stroke 
may not be associated with UGT1A1*28. Similarly, biliru-
bin levels may not be influenced by UGT1A1*28. The main 
purpose of Mendelian randomization is to determine whether 
bilirubin level elevated by UGT1A1*28 can causally affect 
stroke. Our findings suggest no evidence that genetically 
elevated bilirubin level is causally associated with stroke. To 
date, it is uncertain whether decreased total bilirubin levels 
pose an independent risk above and beyond the known risk 
factors.
One of main strengths of the current study lies in its case–
cohort study design from a large prospective cohort study. 
Second, we incorporated multiple bilirubin-associated SNPs 
identified from GWAS to generate WGRS with greater power 
than any single variant in isolation. Finally, we performed 
multivariable Mendelian randomization analysis that allowed 
statistical adjustment for confounders.
However, our analyses must be interpreted in the context 
of the limitations of available data. First, we did not perform 
a replication analysis in an adequately powered second group. 
Therefore, more cohorts are needed to verify these results in 
other populations and other ethnicities in the future. Second, 
because of restricted data, we could not confirm the exact 
Table 3. Association of Serum Total Bilirubin With Stroke Risk Using a Mendelian Randomization Analysis
 
Change in Bilirubin Per Risk Allele
Observational Multivariable Cox 
Proportional Hazard Model*
Mendelian Randomization 
Analysis
β SE F P Value HR P Value HR P Value
UGT1A1 (rs6742078)
  Model 1 0.21 0.010 475 <0.0001 0.52 (0.40–0.67) <0.0001 1.19 (0.44–3.25) 0.731
  Model 2 0.22 0.009 381 <0.0001 0.61 (0.47–0.79) 0.0002 0.75 (0.28–2.01) 0.562
  Model 3 0.22 0.009 171 <0.0001 0.65 (0.50–0.84) 0.001 0.71 (0.26–1.94) 0.501
  Model 4 0.22 0.009 138 <0.0001 0.67 (0.51–0.87) 0.003 0.72 (0.26–2.01) 0.531
WGRS using 14 SNPs
  Model 1 0.44 0.015 866 <0.0001 0.54 (0.42–0.70) <0.0001 0.63 (0.30–1.33) 0.229
  Model 2 0.43 0.014 522 <0.0001 0.63 (0.49–0.83) 0.001 0.63 (0.30–1.35) 0.234
  Model 3 0.43 0.014 233 <0.0001 0.67 (0.52–0.88) 0.004 0.63 (0.30–1.36) 0.240
  Model 4 0.43 0.014 187 <0.0001 0.70 (0.53–0.91) 0.007 0.63 (0.30–1.36) 0.240
Model 1: crude model. Model 2: adjusted for age and sex. Model 3: model 2 plus additional adjustment for systolic blood pressure, 
fasting serum glucose, total cholesterol, and high-density lipoprotein-cholesterol. Model 4: model 3 plus additional adjustment for 
smoking status. HR indicates hazard ratio; SNP, single-nucleotide polymorphism; UGT1A1, uridine diphosphoglucuronyltransferase; and 
WGRS, weighted genetic risk score.
*Cox proportional hazard model that examined bilirubin and stroke.
Figure 2. Mendelian randomization of 
bilirubin level and stroke risk from the 
Korean Cancer Prevention Study-II Bio-
bank. Dotted line reflects that there was 
no association between confounding vari-
ables and UGT1A1. BP indicates blood 
pressure; CI, confidence interval; HDL, 
high-density lipoprotein; and IV, instru-
mental variable.
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recurrent stroke in our analysis. Therefore, we did not fur-
ther analyze the related bilirubin and recurrence of stroke. 
However, we conducted additional analysis between biliru-
bin and stroke subtype using Mendelian randomization. As a 
result, regardless of stroke subtypes, no causal association was 
found between bilirubin and stroke. Third, limitation of our 
study is the potential existence of pleiotropy.31 Genetic variant 
used as IV in Mendelian randomization analysis is associated 
with multiple risk factors. The basic assumption in the analy-
sis of Mendelian randomization is that IV should be associ-
ated with a single exposure variable. However, other unknown 
factors were associated with the IV.
All Mendelian randomization studies are confounded by 
linkage disequilibrium. Therefore, confounding by popula-
tion stratification cannot be completely ruled out. We used the 
multidimensional-scaling method for population stratification 
analysis.32 Because the cluster of our data using multidimen-
sional-scaling was not separated, the matter of population 
stratification in our data does not need to be concerned. The 
majority of the Korean population is ethnically homogenous, 
minimizing a negative effect.33 Despite these limitations, 
Mendelian randomization approach is a useful tool to assess 
the nature of observed associations between putative risk fac-
tors and disease. This approach overcomes some potential 
limitations of observational studies such as the presence of 
confounding variables.34
In summary, the present study demonstrated a significant 
association between SNPs at UGT1 locus and bilirubin lev-
els. However, genetic evidence based on Mendelian ran-
domization approaches suggests no causal effect of bilirubin 
levels on the development of stroke. Further studies are war-
ranted to determine the association between bilirubin level 
and stroke risk.
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Supplementary Table Ⅰ. Association of top 14 SNPs with total serum bilirubin level 34 
based on Korean chip results 35 
SNPID chr 
Closest Ref 
seq gene 
A1 A2 MAF Beta‡ p-value KoGES* Meta† 
rs6742078 2 UGT1A1 T G 0.118 0.207 2.33E-82 o o 
rs6759892 2 UGT1A6 T G 0.244 0.146 1.77E-72 o o 
rs4261716 2 UGT1A7 T G 0.244 0.145 1.09E-71 o o 
rs36075906 2 USP40 T C 0.243 0.071 4.75E-18 x x 
rs4663580 2 DGKD T C 0.058 0.124 1.58E-16 x x 
rs2417940 12 SLCO1B3 T C 0.216 0.067 1.02E-14 o x 
rs2741045 2 UGT1A_locus T C 0.015 0.181 1.17E-10 o o 
rs6758317 2 ATG16L1 T C 0.125 0.062 7.01E-09 x x 
rs11562977 2 TRPM8 T C 0.171 0.050 1.04E-07 x x 
rs12228798 12 SLCO1B3 T C 0.165 0.050 1.60E-07 x x 
rs28898574 2 UGT1A_locus A G 0.013 0.155 3.54E-07 x x 
rs6431631 2 MROH2A A C 0.120 0.055 4.19E-07 o x 
rs16861329 3 ST6GAL1 T C 0.167 0.047 4.36E-07 x x 
rs1042640 2 UGT1A8 C G 0.119 0.054 8.51E-07 x o 
*SNPs in bold are SNPs for total bilirubin levels identified by Kang et al. [2010] 
†The SNPs underlined are SNPs for total bilirubin levels observed in Johnson et al. [2009] 
‘o’ denotes that SNP from Korean chip overlapped with SNPs reported from either 36 
KoGES or Meta-analysis. ‡ Indicated the effect of A1 allele compared with A2 37 
allele.38 
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Supplementary Figure 1. Overall study design 51 
 52 
Supplementary Figure Ⅰ. Overall study design 53 
 54 
KCPS-II Participants Approved by IRB: 270 514
110 670 no inf ormed consent
159 844 inf ormed consent 
Subcohort
5 000
Main cohort
151 701
156 701 blood based cohort
3 008 no blood
135 aged <20 or ov er 85 years old
5 850 GWAS
850 GWAS
(850 Incident stroke)
5 657 GWAS
193 Missing on major variables
5 599 MR (806 Incident stroke)
58 Failed genotyping
5 000 GWAS
(27 Incident stroke)
 55 
Supplementary Figure Ⅱ. Linkage disequilibrium as measured by r2 in UGT1A1 model in the study participants 56 
White: r2=0. Shades of gray: 0<r2<1. Red: r2=1 57 
rs887829
rs10929302
 58 
Supplementary Figure Ⅲ. Significance of SNPs in UGT1A1 model in the study participants 59 
 60 
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 71 
 72 
Supplementary Figure Ⅳ. Summary of significance in the genome wide analysis of total serum bilirubin level in the study 73 
participants. The statistical significance [- log10 (p-value)] from a linear regression that included age and sex as covariates. 74 
Excluded SNPs that a minor allele frequency<0.01, a call rate<0.95 or a deviation from Hardy-Weinberg equilibrium (P<0.0001). 75 
